Download Angiotensin II receptor antagonists : current perspectives by Mancia Giuseppe PDF

By Mancia Giuseppe

ISBN-10: 1841845795

ISBN-13: 9781841845791

On account that angiotensin II is likely one of the such a lot effective vasoconstrictors and an incredible stimulus for the secretion of aldosterone from the adrenal gland, the advance of of angiotensin II inhibitors is a vital step in regulating blood strain. This type of drug is well-tolerated through pateints and those medicinal drugs have the extra virtue over ACE inhibitors in that they're now not linked to cough. simply because such a lot medicines might be given as soon as day-by-day and, like ACEIs, they've got an invaluable additive hypotensive impact together with diuretics, they seem to be a welcome healing device within the therapy of high blood pressure. This moment variation builds at the good fortune of the 1st and brings to the reader the entire most modern advancements, scientific trial information, and the contributors's own views while treating sufferers with angiotensin II receptors antagonists.

  • offers chapters by way of famous participants within the fields of either high blood pressure and center failure, specifically with reference to pharmacological interventions
  • covers the recent function of AIIR in neuroprotection
  • builds upon the strengths of the 1st edition
  • Show description

    Read Online or Download Angiotensin II receptor antagonists : current perspectives PDF

    Best cardiovascular books

    Atrial Flutter - A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References

    It is a 3-in-1 reference booklet. It offers a whole scientific dictionary masking hundreds of thousands of phrases and expressions when it comes to atrial flutter. It additionally offers large lists of bibliographic citations. eventually, it presents details to clients on the best way to replace their wisdom utilizing numerous net assets.

    Biomarkers in Heart Disease (American Heart Association Clinical Series)

    Biomarkers in middle affliction is the 1st identify within the AHA scientific sequence and is geared toward assembly the wishes of clinicians, supplying cardiologists, internists, emergency physicians, laboratorians, and different healthcare services with a transparent figuring out of the function of biomarkers in modern cardiovascular medication.

    Atrial Fibrillation Ablation, 2011 Update: The State of the Art Based on the VeniceChart International Consensus Document

    This concise textual content offers top practices for all elements of atrial traumatic inflammation ablation as defined within the re-creation of the VeniceChart foreign Consensus record, that is provided along with the biannual Venice Arrhythmias convention. as well as discussing the most recent in a-fib ablation study, this 2011 replace covers the entire key components of remedy and sufferer administration, together with: • suggestions and applied sciences • Procedural endpoints • sufferer administration pre-, peri- and post-ablation • Prevention and therapy of problems • Definition of luck and long term effects With contributions from the world’s famous notion leaders during this box, this booklet is a hugely worthwhile resource of data not just for experts in electrophysiology, but in addition for basic cardiologists, fellows in cardiology and others drawn to this dynamic and more and more vital subject.

    Extra info for Angiotensin II receptor antagonists : current perspectives

    Sample text

    Identification of a highly specific chymase as the major angiotensin II forming enzyme in the human heart. J Biol Chem 1990; 265:22348–57. 5. Kleinert HD. Renin inhibition. Cardiovasc Drugs Ther 1995; 9:645–55. 6. Gradman AH, Schmeider PR, Lins RL et al. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation 2005; 111:1012–18. 7. Streeten DHP. Outpatient experience with saralasin.

    Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997; 349:747–52. 29. Dahlöf B, Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359:995–1003. 30. Puig JG, Mateos F, Buno A et al. Effect of eprosartan and losartan on uric acid metabolism in patients with essential hypertension.

    Burnier M. Angiotensin II type 1 receptor blockers. Circulation 2001; 103:904–12. 15. Lacourière Y, Lefebvre J, Nakhla G et al. Association between cough and angiotensin converting enzyme inhibitors versus angiotensin II antagonists: the design of a prospective, controlled study. J Hypertens 1994; 12(Suppl):49–53. 16. Johnston CI, Risvanis J. Preclinical pharmacology of angiotensin II-receptor antagonists. Am J Hypertens 1997; 10:306–10S. 17. Unger T, Chung O, Csikos T et al. Angiotensin receptors.

    Download PDF sample

    Rated 4.00 of 5 – based on 47 votes